Hairy Cell Leukemia

临床试验

计划入组 210 人 · 首次发布于 2014 年 5 月 6 日

已完成

NCT00001567

A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia

计划入组 56 人 · 首次发布于 1999 年 11 月 4 日

终止

NCT00924040

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

计划入组 1 人 · 首次发布于 2009 年 6 月 18 日

药物

查看全部 4621 →

Small Molecule

Approved

Pentostatin(Nipent)

生产企业：Hospira inc, Bedford laboratories

相关疾病：Acute Graft-Versus-Host Disease (GVHD), B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory，另有 5 项

C₁₁H₁₆N₄O₄

Biotech

Approved

Interferon alfa-2b(Intron A)

相关疾病：Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection，另有 5 项

Biotech

Approved

Moxetumomab pasudotox(Lumoxiti)

相关疾病：Relapsed/Refractory Hairy Cell Leukemia

机构

查看全部 161 →

JAPAN ADULT LEUKEMIA STUDY GROUP

Japan

Gamida Cell

Israel

GAMIDA CELL INC.

United States

资讯

查看全部 12523 →

上个月

Weekly Cladribine Plus Rituximab Shows Promise Against Hairy Cell Leukemia

去年

BRAF Inhibitors Show Promise in Treatment of Relapsed/Refractory Hairy Cell Leukemia

3年前

临床试验

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

药物

Pentostatin(Nipent)

Interferon alfa-2b(Intron A)

Moxetumomab pasudotox(Lumoxiti)

机构

JAPAN ADULT LEUKEMIA STUDY GROUP

Gamida Cell

GAMIDA CELL INC.

资讯

Weekly Cladribine Plus Rituximab Shows Promise Against Hairy Cell Leukemia

BRAF Inhibitors Show Promise in Treatment of Relapsed/Refractory Hairy Cell Leukemia

AstraZeneca Discontinues Moxetumomab Pasudotox for Hairy Cell Leukemia Due to Low Clinical Uptake